Prevention of delirium in acute stroke

Phase 3

Withdrawn

• Conditions: confusion; mental confusion; 10007963; 10012221

• Registration Number: NL-OMON35482
• Lead Sponsor: Kennemer Gasthuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

- Patients with (suspected) stroke
- no delirium on admission (DRS<12; CAM < 2+1)
- expected duration of hospitalisation >48 hours
- Score on deliersticker * 5
- Time between admission and estimation of risk score and DRS/CAM < 24 hours

Exclusion Criteria

- Score deliersticker < 5
- delirium on admission (DRS> 12; CAM * 2+1; CAM-ICU * 2 + 1)
- not able to perform delirum screening (DRS, CAM, CAM-ICU) on admission
- expected duriong of hospitalisation < 48 uur
- contraindication for use of haloperidol: history of allergy for haloperidol, severe liverinsufficiency, Parkinson's disease, Lewy body dementia, parkinsonism, epilepsy, use of levodopa/dopamine agonist, use of antipsychotics (e.g., haloperidol) or cholinesterase inhibitors
- Pronged Qt interval: Qt interval on EKG on admission * 500ms .
- Time between admission and estimation of risk score and DRS/CAM < 24 hours
- Participation in same study in the last three months
- severe impairment of consciousness (coma)
- not possible to obtain informed consent
- Patients, family of physician refuse to participate

Study & Design

• Study Type: Interventional
• Study Design: Not specified